591 related articles for article (PubMed ID: 25713428)
1. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
Hensley ML; Blessing JA; Mannel R; Rose PG
Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
Hensley ML; Ishill N; Soslow R; Larkin J; Abu-Rustum N; Sabbatini P; Konner J; Tew W; Spriggs D; Aghajanian CA
Gynecol Oncol; 2009 Mar; 112(3):563-7. PubMed ID: 19135708
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Kelly WK; Halabi S; Carducci M; George D; Mahoney JF; Stadler WM; Morris M; Kantoff P; Monk JP; Kaplan E; Vogelzang NJ; Small EJ
J Clin Oncol; 2012 May; 30(13):1534-40. PubMed ID: 22454414
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
[TBL] [Abstract][Full Text] [Related]
9. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
[TBL] [Abstract][Full Text] [Related]
11. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Kindler HL; Karrison TG; Gandara DR; Lu C; Krug LM; Stevenson JP; Jänne PA; Quinn DI; Koczywas MN; Brahmer JR; Albain KS; Taber DA; Armato SG; Vogelzang NJ; Chen HX; Stadler WM; Vokes EE
J Clin Oncol; 2012 Jul; 30(20):2509-15. PubMed ID: 22665541
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
13. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
Reck M; von Pawel J; Zatloukal P; Ramlau R; Gorbounova V; Hirsh V; Leighl N; Mezger J; Archer V; Moore N; Manegold C
J Clin Oncol; 2009 Mar; 27(8):1227-34. PubMed ID: 19188680
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G
J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
[TBL] [Abstract][Full Text] [Related]
17. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Van Cutsem E; Vervenne WL; Bennouna J; Humblet Y; Gill S; Van Laethem JL; Verslype C; Scheithauer W; Shang A; Cosaert J; Moore MJ
J Clin Oncol; 2009 May; 27(13):2231-7. PubMed ID: 19307500
[TBL] [Abstract][Full Text] [Related]
19. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
